Overview

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

Status:
RECRUITING

Trial end date:
2028-11-27

Target enrollment:

Participant gender:

Summary

This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).

Phase:

PHASE2

Details

Lead Sponsor:

Novartis Pharmaceuticals